AR077487A2 - Composiciones atenuadas para dialisis - Google Patents
Composiciones atenuadas para dialisisInfo
- Publication number
- AR077487A2 AR077487A2 ARP100102606A ARP100102606A AR077487A2 AR 077487 A2 AR077487 A2 AR 077487A2 AR P100102606 A ARP100102606 A AR P100102606A AR P100102606 A ARP100102606 A AR P100102606A AR 077487 A2 AR077487 A2 AR 077487A2
- Authority
- AR
- Argentina
- Prior art keywords
- citrate
- acetate
- lactate
- precursor composition
- magnesium
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 238000000502 dialysis Methods 0.000 title 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 6
- 239000002243 precursor Substances 0.000 abstract 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 3
- -1 hydrogen disodium citrate Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 2
- XQKKWWCELHKGKB-UHFFFAOYSA-L calcium acetate monohydrate Chemical compound O.[Ca+2].CC([O-])=O.CC([O-])=O XQKKWWCELHKGKB-UHFFFAOYSA-L 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000008103 glucose Substances 0.000 abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 abstract 2
- 235000017281 sodium acetate Nutrition 0.000 abstract 2
- 239000001509 sodium citrate Substances 0.000 abstract 2
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-L 2-(carboxymethyl)-2-hydroxysuccinate Chemical compound [O-]C(=O)CC(O)(C(=O)O)CC([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-L 0.000 abstract 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- 229930091371 Fructose Natural products 0.000 abstract 1
- 239000005715 Fructose Substances 0.000 abstract 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 abstract 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 239000001639 calcium acetate Substances 0.000 abstract 1
- 235000011092 calcium acetate Nutrition 0.000 abstract 1
- 229960005147 calcium acetate Drugs 0.000 abstract 1
- 229940067460 calcium acetate monohydrate Drugs 0.000 abstract 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 abstract 1
- 239000001354 calcium citrate Substances 0.000 abstract 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 abstract 1
- 239000001527 calcium lactate Substances 0.000 abstract 1
- 235000011086 calcium lactate Nutrition 0.000 abstract 1
- 229960002401 calcium lactate Drugs 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 239000012141 concentrate Substances 0.000 abstract 1
- 239000002526 disodium citrate Substances 0.000 abstract 1
- 235000019262 disodium citrate Nutrition 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229940001447 lactate Drugs 0.000 abstract 1
- 239000004310 lactic acid Substances 0.000 abstract 1
- 235000014655 lactic acid Nutrition 0.000 abstract 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 abstract 1
- 239000011654 magnesium acetate Substances 0.000 abstract 1
- 235000011285 magnesium acetate Nutrition 0.000 abstract 1
- 229940069446 magnesium acetate Drugs 0.000 abstract 1
- 229940097364 magnesium acetate tetrahydrate Drugs 0.000 abstract 1
- 239000004337 magnesium citrate Substances 0.000 abstract 1
- 229960005336 magnesium citrate Drugs 0.000 abstract 1
- 235000002538 magnesium citrate Nutrition 0.000 abstract 1
- SNLQXUYQWUDJLB-UHFFFAOYSA-L magnesium;2-hydroxypropanoate;trihydrate Chemical compound O.O.O.[Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O SNLQXUYQWUDJLB-UHFFFAOYSA-L 0.000 abstract 1
- XKPKPGCRSHFTKM-UHFFFAOYSA-L magnesium;diacetate;tetrahydrate Chemical compound O.O.O.O.[Mg+2].CC([O-])=O.CC([O-])=O XKPKPGCRSHFTKM-UHFFFAOYSA-L 0.000 abstract 1
- 235000011056 potassium acetate Nutrition 0.000 abstract 1
- 229960004109 potassium acetate Drugs 0.000 abstract 1
- 239000001508 potassium citrate Substances 0.000 abstract 1
- 229960002635 potassium citrate Drugs 0.000 abstract 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 abstract 1
- 235000011082 potassium citrates Nutrition 0.000 abstract 1
- PHZLMBHDXVLRIX-UHFFFAOYSA-M potassium lactate Chemical compound [K+].CC(O)C([O-])=O PHZLMBHDXVLRIX-UHFFFAOYSA-M 0.000 abstract 1
- 239000001521 potassium lactate Substances 0.000 abstract 1
- 235000011085 potassium lactate Nutrition 0.000 abstract 1
- 229960001304 potassium lactate Drugs 0.000 abstract 1
- 239000001632 sodium acetate Substances 0.000 abstract 1
- 229960004249 sodium acetate Drugs 0.000 abstract 1
- 229940087562 sodium acetate trihydrate Drugs 0.000 abstract 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 abstract 1
- 235000011083 sodium citrates Nutrition 0.000 abstract 1
- 239000001540 sodium lactate Substances 0.000 abstract 1
- 235000011088 sodium lactate Nutrition 0.000 abstract 1
- 229940005581 sodium lactate Drugs 0.000 abstract 1
- 235000013337 tricalcium citrate Nutrition 0.000 abstract 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 abstract 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 abstract 1
- 229940038773 trisodium citrate Drugs 0.000 abstract 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Los concentrados de acido, y las composiciones dialiticas de esos, contienen ácido cítrico y una cantidad efectiva de un agente atenuante, seleccionado entre acetato y/o Iactato. El agente atenuante permite una cantidad fisiologicamente aceptable de citrato para mantener el pH deseado de dialitico. Reivindicacion 1: Una composicion precursora para preparar un dialitico atenuado, la composicion precursora comprendiendo de citrato en una concentracion que varia desde alrededor de 20 a alrededor de 900 mEq/L; un atenuante; agua; cloruro en una concentracion que varia desde alrededor de 1.000 a alrededor de 7.000 nEq/L; y al menos un cation fisiologicamente aceptable. Reivindicacion 9: La composicion precursora de las reivindicaciones 1-8, que además comprende de un azucar seleccionado de la glucosa, una poli(glucosa), y fructosa, en una concentracion de menos de alrededor de 2.700 g/L. Reivindicacion 10: La composicion precursora de las reivindicaciones 1-9, en la cual el citrato está en la forma de al menos un ácido cítrico y una sal de ese, seleccionados de un grupo que consiste de citrato de sodio bihidrato, citrato de hidrogeno disodio, citrato trisodio, citrato bihidrato trisodio, citrato de potasio bihidrato, citrato de hidrogeno bipotasio, citrato de calcio, y citrato de magnesio; en donde el acetato de anion atenuante está en la forma de al menos un ácido acético y una sal de ese, seleccionados de un grupo que consiste de acetato de sodio, acetato de sodio trihidrato, acetato de potasio, acetato de calcio, acetato de calcio monohidrato, acetato de magnesio, y acetato de magnesio tetrahidrato; y en donde el lactato del anion atenuante está en la forma de al menos un ácido láctico y una sal de ese, seleccionados de un grupo que consiste de lactato de sodio, lactato de potasio, lactato de calcio y lactato de magnesio trihidrato.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17606398A | 1998-10-20 | 1998-10-20 | |
| US10504998P | 1998-10-20 | 1998-10-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR077487A2 true AR077487A2 (es) | 2011-08-31 |
Family
ID=26802194
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990105299A AR020918A1 (es) | 1998-10-20 | 1999-10-20 | Composiciones atenuadas para dialisis |
| ARP100102606A AR077487A2 (es) | 1998-10-20 | 2010-07-16 | Composiciones atenuadas para dialisis |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990105299A AR020918A1 (es) | 1998-10-20 | 1999-10-20 | Composiciones atenuadas para dialisis |
Country Status (21)
| Country | Link |
|---|---|
| EP (3) | EP1124567B2 (es) |
| JP (3) | JP4932084B2 (es) |
| CN (1) | CN1188136C (es) |
| AR (2) | AR020918A1 (es) |
| AT (1) | ATE321563T1 (es) |
| AU (1) | AU765029B2 (es) |
| BR (1) | BR9914644A (es) |
| CA (1) | CA2347447C (es) |
| CO (1) | CO5160318A1 (es) |
| CY (1) | CY1107496T1 (es) |
| DE (2) | DE69930676D1 (es) |
| DK (2) | DK1124567T4 (es) |
| EG (1) | EG24303A (es) |
| ES (2) | ES2262363T5 (es) |
| IL (2) | IL142648A0 (es) |
| MX (1) | MXPA01003969A (es) |
| MY (1) | MY125622A (es) |
| NZ (1) | NZ511172A (es) |
| PT (2) | PT1124567E (es) |
| TW (1) | TWI240630B (es) |
| WO (1) | WO2000023086A2 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7670491B2 (en) * | 1998-10-20 | 2010-03-02 | Advanced Renal Technologies | Buffered compositions for dialysis |
| ES2322689T3 (es) * | 1999-09-22 | 2009-06-25 | Advanced Renal Technologies | Uso de un dializado con elevado contenido de citrato. |
| GR1003567B (el) * | 2000-06-28 | 2001-04-10 | Νεωτερα ενιαια και σταθερα αμινοξεων-διττανθρακικων πλεονεκτικα διαλυματα για την περιτοναικη καθαρση και αιμοκαθαρση. | |
| JP5204359B2 (ja) * | 2001-09-28 | 2013-06-05 | 味の素株式会社 | 透析用剤およびその製造方法 |
| US7053059B2 (en) * | 2003-07-25 | 2006-05-30 | Baxter International Inc. | Dialysis solutions with reduced levels of glucose degradation products |
| US8367731B2 (en) | 2005-05-30 | 2013-02-05 | Fresenius Medical Care Deutschland Gmbh | Peritoneal dialysis fluid |
| JP5371278B2 (ja) * | 2008-04-03 | 2013-12-18 | エイワイファーマ株式会社 | 透析用剤およびその製造方法 |
| JP5560539B2 (ja) * | 2008-06-13 | 2014-07-30 | ニプロ株式会社 | 透析液調製装置 |
| ES2332636B1 (es) * | 2008-08-06 | 2011-02-10 | Universitat De Les Illes Balears | Composicion de liquido de dialisis. |
| MX370297B (es) | 2009-06-17 | 2019-12-09 | Fresenius Medical Care Holdings Inc | Procedimientos de diálisis de anticoagulación regional con citrato. |
| RU2438663C1 (ru) | 2010-10-18 | 2012-01-10 | Общество с ограниченной ответственностью "Научно-производственное объединение "Нефрон" (ООО "НПО "Нефрон") | Способ получения гемодиализирующего раствора для бикарбонатного гемодиализа |
| CH712274B1 (fr) * | 2016-03-18 | 2020-06-30 | Hemo Plus Sarl | Unité pour la préparation d'au moins une solution de concentrés pour hémodialyse et procédé de préparation de cette solution. |
| EP3618888A4 (en) * | 2017-05-05 | 2021-05-05 | Fresenius Medical Care Deutschland GmbH | PERITONEAL DIALYSIS CONCENTRATE, PERITONEAL DIALYSIS BAG AND SET FOR CONTINUOUS AMBULANCE PERITONEAL DIALYSIS OR AUTOMATED PERITONEAL DIALYSIS |
| CN107281098A (zh) * | 2017-06-30 | 2017-10-24 | 华仁药业股份有限公司 | 一种血液滤过置换液 |
| CN107890568A (zh) * | 2017-10-31 | 2018-04-10 | 华仁药业股份有限公司 | 一种低危害的血液滤过置换液及其制备工艺 |
| CN112167264B (zh) * | 2020-10-28 | 2021-10-26 | 广州吾同生态科技有限公司 | 一种次氯酸电解液、次氯酸消毒液及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2929871A1 (de) | 1979-07-24 | 1981-01-29 | Gambro Dialysatoren | Waessriges konzentrat fuer dialyse-loesungen |
| US5252213A (en) * | 1989-06-20 | 1993-10-12 | University Of Washington | Dry dialysate composition |
| EP0457960A3 (en) * | 1990-05-17 | 1993-01-07 | Minntech Corporation | High acid concentration dialysates |
| CA2098839C (en) * | 1990-12-18 | 2001-03-13 | Suhail Ahmad | Dialysate production system with dialysate pellets |
| DE4114908A1 (de) * | 1991-05-07 | 1992-11-12 | Klaus Dr Med Sodemann | Dialyseloesung zur dialysebehandlung, konzentrat und vorrichtung zur dialysebehandlung |
| AU4239593A (en) * | 1992-06-03 | 1993-12-30 | Minntech Corporation | Method of hemodialysis and hemodialysis liquids including hydrochloric acid |
| JP3398184B2 (ja) * | 1993-03-30 | 2003-04-21 | 味の素ファルマ株式会社 | 透析用剤 |
| JP3384841B2 (ja) * | 1993-04-02 | 2003-03-10 | 味の素ファルマ株式会社 | 重曹透析用剤 |
| ATE222766T1 (de) * | 1994-07-01 | 2002-09-15 | Baxter Int | Biochemisch isotone peritonealdialyselösungen |
| JP3530235B2 (ja) * | 1994-09-27 | 2004-05-24 | 味の素ファルマ株式会社 | 血液透析用剤 |
| DE19631124A1 (de) * | 1996-08-01 | 1998-02-05 | Fresenius Medical Care De Gmbh | Verfahren zur Herstellung einer Bicarbonat enthaltenden Infusions- oder Dialysierlösung |
| JP3619921B2 (ja) * | 1996-09-13 | 2005-02-16 | 富田製薬株式会社 | 重炭酸固形透析用剤 |
| DE19654746C2 (de) | 1996-12-30 | 2000-05-11 | Klaus Sodemann | Dialyselösung |
-
1999
- 1999-10-18 EG EG129699A patent/EG24303A/xx active
- 1999-10-19 PT PT99970600T patent/PT1124567E/pt unknown
- 1999-10-19 MX MXPA01003969A patent/MXPA01003969A/es active IP Right Grant
- 1999-10-19 DK DK99970600.5T patent/DK1124567T4/da active
- 1999-10-19 EP EP99970600A patent/EP1124567B2/en not_active Expired - Lifetime
- 1999-10-19 DK DK06006408.6T patent/DK1721606T3/da active
- 1999-10-19 NZ NZ511172A patent/NZ511172A/xx not_active IP Right Cessation
- 1999-10-19 WO PCT/US1999/024583 patent/WO2000023086A2/en not_active Ceased
- 1999-10-19 DE DE69930676A patent/DE69930676D1/de not_active Expired - Lifetime
- 1999-10-19 IL IL14264899A patent/IL142648A0/xx active IP Right Grant
- 1999-10-19 EP EP06006408.6A patent/EP1721606B1/en not_active Expired - Lifetime
- 1999-10-19 JP JP2000576860A patent/JP4932084B2/ja not_active Expired - Lifetime
- 1999-10-19 CA CA002347447A patent/CA2347447C/en not_active Expired - Lifetime
- 1999-10-19 AT AT99970600T patent/ATE321563T1/de active
- 1999-10-19 ES ES99970600T patent/ES2262363T5/es not_active Expired - Lifetime
- 1999-10-19 PT PT60064086T patent/PT1721606E/pt unknown
- 1999-10-19 BR BR9914644-4A patent/BR9914644A/pt not_active Application Discontinuation
- 1999-10-19 EP EP20110190795 patent/EP2452685A1/en not_active Withdrawn
- 1999-10-19 DE DE69930676T patent/DE69930676T3/de not_active Expired - Lifetime
- 1999-10-19 AU AU14481/00A patent/AU765029B2/en not_active Ceased
- 1999-10-19 ES ES06006408.6T patent/ES2438971T3/es not_active Expired - Lifetime
- 1999-10-19 MY MYPI99004515A patent/MY125622A/en unknown
- 1999-10-19 CN CNB998135658A patent/CN1188136C/zh not_active Expired - Fee Related
- 1999-10-20 TW TW088118133A patent/TWI240630B/zh not_active IP Right Cessation
- 1999-10-20 AR ARP990105299A patent/AR020918A1/es active IP Right Grant
- 1999-10-20 CO CO99066230A patent/CO5160318A1/es unknown
-
2001
- 2001-04-17 IL IL142648A patent/IL142648A/en not_active IP Right Cessation
-
2006
- 2006-06-22 CY CY20061100846T patent/CY1107496T1/el unknown
-
2010
- 2010-07-16 AR ARP100102606A patent/AR077487A2/es unknown
-
2011
- 2011-10-19 JP JP2011229528A patent/JP2012066088A/ja active Pending
-
2013
- 2013-09-27 JP JP2013201021A patent/JP5975962B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR077487A2 (es) | Composiciones atenuadas para dialisis | |
| JP2945718B2 (ja) | 冷蔵庫温度で安定なホリニン酸塩水溶液並びにその製造方法 | |
| TWI583378B (zh) | 透析酸前驅物組成物、其用途、以及提供透析酸濃縮物溶液之方法 | |
| KR101831007B1 (ko) | 투석 전구체 조성물 | |
| EP2720678B1 (en) | Dialysis precursor composition | |
| IE48122B1 (en) | Solutions for use in a therapeutical method of treating chronic uraemic patients undergoing dialysis | |
| US4405600A (en) | Methods and materials for prevention of carious degradation of teeth | |
| EP2720700B1 (en) | Dialysis precursor composition | |
| ES8502873A1 (es) | Metodo de preparacion de soluciones para dialisis. | |
| US3560380A (en) | Dry concentrates for preparing hemodialysis solutions | |
| JP2001527574A (ja) | 眼科用組成物 | |
| JP2012066088A5 (es) | ||
| JP2010513487A5 (es) | ||
| JPS5944375A (ja) | α−トコフエロ−ルリン酸エステルの安定な水溶液 | |
| ATE141519T1 (de) | Kontrastmittel enthaltend einen nicht-ionischen kontrast wirkstoff und sodium und kalzium sälze | |
| EP0101185B2 (en) | Transfusion preparation for intravenous infusion | |
| EP0189405B1 (en) | Disinfection of contact lenses | |
| Herrera | Inhibition of lithium transport across toad bladder by amiloride | |
| JPS6363616A (ja) | 赤血球濃厚液の保存剤及び保存方法 | |
| JP2000507217A (ja) | 安定性が増大した低ｐＨの殺菌性ヨウ素組成物 | |
| JP2016503768A (ja) | 透析組成物 | |
| JP5112872B2 (ja) | 創傷および火傷を治療するための組成物 | |
| ES8308215A1 (es) | "procedimiento para preparar una composicion de conservacion de lentes de contacto blandas". | |
| EP2793903B1 (en) | Dialysis precursor composition | |
| EP2793902B1 (en) | Dialysis precursor composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |